The
slide to be stained for
CK20
comprised:
1. Colon adenocarcinoma, 2. Merkel cell carcinoma, 3. Colon
adenocarcinoma, 4. Appendix
5. Gastric corpus, and 6. Urothelial carcinoma.
All tissues were fixed in 10% neutral buffered formalin.
Criteria for assessing a CK20 staining as optimal included:
- A strong, distinct cytoplasmic staining reaction of all the surface
epithelial cells of the appendix and at least a weak to moderate
staining reaction in most crypt cells.
- An at least moderate, distinct cytoplasmic staining reaction of the
majority of the foveolar epithelial cells of the stomach.
- A moderate to strong, distinct cytoplasmic staining reaction in
virtually all the neoplastic cells of the colon adenocarcinoma no. 3
and focally in the colon adenocarcinoma no. 1.
- A moderate to strong, distinct dot-like intracytoplasmic staining
reaction in virtually all the neoplastic cells of the Merkel cell
carcinoma.
- An at least weak to moderate, distinct cytoplasmic staining reaction
in the majority of the neoplastic cells of the urothelial carcinoma.
196 laboratories participated in this assessment. One lab submitted
an inappropriate antibody (Ab), namely CK-LMW. Out of the remaining 195 labs 85
% achieved a sufficient mark. In table 1 the Abs used
and marks are summarized.
Table 1.
Abs and
assessment marks
for CK20, run 35
|
Concentrated Abs |
N |
Vendor |
Optimal |
Good |
Borderl. |
Poor |
Suff.1 |
Suff. OPS2 |
|
mAb clone Ks20.8 |
92
10
2
2
2
1
1
1
1
1 |
Dako
Leica/Novocastra
Cell Marque
Eurodiagnostics
Thermo/NeoMarkers
Biocare
DBS
Europroxima
Master Diagnostica
Progen |
56 |
42 |
12 |
3 |
87 % |
91 % |
|
mAb clone PW31 |
1 |
Leica/Novocastra |
0 |
0 |
1 |
0 |
- |
- |
|
rmAb clone EP23 |
1 |
Epitomics |
0 |
1 |
0 |
0 |
- |
- |
|
pAb E16444 |
7 |
Spring Bioscience |
4 |
3 |
0 |
0 |
100 % |
100 % |
|
Unknown |
1 |
Unknown |
0 |
1 |
0 |
0 |
- |
- |
|
Ready-To-Use Abs |
|
|
|
|
|
|
|
|
mAb clone Ks20.8
IR/IS777 |
25 |
Dako |
13 |
12 |
0 |
0 |
100 % |
100 % |
mAb clone Ks20.8
PM062 |
1 |
Biocare |
0 |
0 |
1 |
0 |
- |
- |
mAb clone Ks20.8
320M-17 |
1 |
Cell Marque |
0 |
1 |
0 |
0 |
- |
- |
mAb clone Ks20.8
RTU-CK20 |
1 |
Leica/Novocastra |
0 |
1 |
0 |
0 |
- |
- |
mAb clone Ks20.8
E062 |
1 |
Linaris |
1 |
0 |
0 |
0 |
- |
- |
mAb clone Ks20.8
mon-rtu1083 |
1 |
Monosan |
0 |
0 |
1 |
0 |
- |
- |
mAb clone Ks20.8
ZM-0075 |
1 |
Zhongshan |
0 |
1 |
0 |
0 |
- |
- |
mAb clone PW31
PA0918 |
4 |
Leica/Novocastra |
0 |
0 |
4 |
0 |
- |
- |
rmAb clone SP33
790-4431 |
37 |
Ventana |
20 |
10 |
6 |
1 |
81 % |
100 % |
|
Total |
195 |
|
94 |
72 |
25 |
4 |
- |
|
|
Proportion |
|
|
48 % |
37 % |
13 % |
2 % |
85 % |
|
1) Proportion of sufficient stains
(optimal or good), 2) Proportion of sufficient stains with optimal
protocol settings only, see below.
Following central protocol parameters were used to obtain an optimal
staining:
Concentrated Abs mAb clone Ks20.8:
The protocols giving an optimal result were based
on either heat induced epitope retrieval (HIER),
enzymatic
pre-treatment or a combination of HIER and enzymatic pre-treatment.
In total 56 optimal stains were seen with the use of one of these
three pre-treatment procedures.
51 out of the 56 laboratories obtaining an optimal staining result
used HIER in either Target Retrieval Solution pH 9 (3-in-1) (TRS pH
9; Dako) (8/20)*, TRS pH 9 (Dako) (3/9), Cell Conditioning 1 (CC1;
BenchMark, Ventana) (17/29), Bond Epitope Retrieval Solution 2 (BERS
2; Bond, Leica) (13/17), Borg Decloaker pH 9.5 (Biocare) (1/2),
Tris-EDTA/EGTA pH 9 (8/16) or EDTA/EGTA pH 8 (1/1) as the retrieval
buffer. The mAb was typically diluted in the range of 1:25-1:400 depending
on the total sensitivity of the protocol employed. Using these
protocol settings 87 out of 96 (91 %) laboratories produced a
sufficient staining (optimal or good).
* (number of optimal results/number of laboratories using this
reagent)
3 laboratories obtaining an optimal staining result used enzymatic
pre-treatment as Protease 1 (Benchmark, Ventana) (2/11) or Bond
Enzyme 1 (1/2). The mAb was typically diluted in the range of 1:50-1:150 depending
on the total sensitivity of the protocol employed. Using these
protocol settings 7 out of 8 (88 %) laboratories produced a
sufficient staining.
2 laboratories obtaining an optimal staining result used a combined
pre-treatment using Protease 3 (Benchmark, Ventana) and HIER in CC1
(Benchmark, Ventana) (2/2). The mAb was diluted 1:50-80. Using these
protocol settings 2 out of 2 laboratories produced an optimal
staining.
pAb E16444: The protocols giving an optimal result were all based
on HIER using either CC1 (BenchMark, Ventana) (2/4), Tris-EDTA/EGTA pH
9 (1/1) or Citrate pH 6 (1/1) as the retrieval buffer. The pAb
was diluted in the range of 1:50-1:400 depending on the total
sensitivity of the protocol employed. Using these protocol settings
7 out of 7 (100 %) laboratories produced a sufficient staining.
Ready-To-Use Abs mAb clone Ks20.8 (prod. no. IS/IR777, Dako): The protocols giving an
optimal result were all based on HIER in PT-Link (heating time for
10-20 min at 97°C) using TRS pH 9 (3-in-1) (Dako) or TRS pH 9 (Dako)
as HIER buffer, an incubation time of 20 min in the primary Ab and
EnVision Flex or EnVision Flex+ (K8000/K8002) as the detection
system. Using these protocol settings 20 out of 20 (100 %)
laboratories produced a sufficient staining.
rmAb clone SP33 (prod. no. 790-4431, Ventana): The protocols giving
an optimal result were typically based on HIER using mild or
standard CC1, an incubation time of 16-32 min in the primary Ab and
UltraView (760-500) +/- amplification or OptiView (760-700) as the
detection system. Using these protocol settings 27 out of 27 (100 %)
laboratories produced a sufficient staining.
The most frequent causes of insufficient stains were:
- Too low concentration of the primary Ab - Less successful primary Ab - Use of biotin based detection systems
(giving a false positive
staining due to endogenous biotin).
In this assessment and in concordance
with the previous NordiQC runs
for CK20, the prevalent feature of an insufficient staining reaction
was a general too weak staining or a false negative staining of the
structures expected to be demonstrated. Virtually all laboratories
could demonstrate CK20 in the luminal epithelial cells of the
appendix and in the neoplastic cells of the colon adenocarcinomas
and the Merkel cell carcinoma, whereas the demonstration of CK20 in
the foveolar epithelial cells of the stomach and in the neoplastic
cells in the urothelial carcinoma was more challenging and required
a correctly calibrated protocol. A too weak or false negative staining reaction was seen in 83 % of
the insufficient results and was mainly caused by a too low
concentration of the primary Ab or using a less successful clone as
the mAb clone PW31, Leica, which gave an insufficient result in all
5 out 5 protocols based on this clone. In 17 % both a too weak and a false positive staining reaction was
observed. The false positive staining reaction was observed when a
biotin based detection system was used in combination with efficient
HIER and was mainly seen as a granular intracytoplasmic staining
reaction in the epithelial cells of the gastric crypt epithelium.
In the previous NordiQC assessment for CK20, run 25, 2009, HIER
showed to give a significantly higher pass rate compared to
enzymatic pre-treatment for the most widely used mAb clone Ks20.8.
If HIER was used a pass rate of 76 % was seen (76 out of 100 labs),
compared to 19 % if enzymatic pre-treatment was used (5 out of 26
labs). In this assessment only 12 laboratories used enzymatic
pre-treatment for the mAb clone Ks20.8 and for these laboratories a
pass rate of 58 % was seen, whereas a pass rate of 91 % was seen if
HIER was performed (114 out of 126 labs).
In this assessment
gastric corpus mucosa was the most appropriate control for
CK20, as both the sensitivity and specificity (regarding endogenous
biotin) could be evaluated in this tissue. The majority of the foveolar epithelial cells must show an at least weak to moderate
cytoplasmic staining reaction, while other epithelial cells must be negative
(apart from neuroendocrine cells).
This was the 3rd assessment of CK20 in NordiQC (Table 2) and a
significant increase in the pass rate was seen compared to run 25.
Table 2:
Proportion of sufficient results for CK20 in the three NordiQC runs
performed
The significant improvement of the pass rate for CK20 can by
be influenced by many parameters including new and less challenging
material circulated. However, as the most challenging tissues in the
previous run and this run being the gastric corpus and the urothelial
carcinoma both were incorporated in the multi-tissueblocks constructed for
the two runs, this supports that an
improvement was achieved. The improvement most likely was related to
the reduced use of enzymatic pre-treatment, which in both this run
and the previous run has shown to be less successful compared to HIER for the mAb clone Ks20.8. In run 25, 21 % of the laboratories
used enzymatic pre-treatment compared to 8 % in this run for the mAb
clone Ks20.8. It was also related to the high quality and extended
use of the Ready-To-Use (RTU) systems for CK20 from the two main
providers Dako and Ventana, as the RTU systems from these two
companies in this assessment showed a pass-rate of 100 % thus being
superior to the pass-rates for the in-house validated protocols for
CK20. The recently launched RTU system from Ventana based on the
rmAb clone SP33 showed a superior performance in this run compared
to the previous Ventana RTU system based on the mAb clone Ks20.8
used by the laboratories in run 25, where a pass rate of only 50 %
was seen.
Conclusion The mAb clone Ks20.8 and the pAb
E16444 are both
recommendable Abs for CK20. For both Abs, HIER is preferred
to obtain an optimal staining. The RTU systems from Dako and Ventana, based on the mAb clone Ks20.8
and the rmAb clone SP33 respectively, gave a pass rate of 100 %
with optimal protocol settings, thus being superior to the in-house validated assays. Gastric corpus
mucosa is recommended as positive control: The majority of the foveolar cells must show an at least weak to moderate cytoplasmic
staining reaction. Alternatively appendix can be used: Virtually all
the luminal epithelial cells must show a strong cytoplasmic staining
reaction, while the majority of the crypt epithelial cells an at
least weak cytoplasmic staining reaction. |